Trial Profile
A Phase 2a, Multicenter, Randomized, Parallel, Double-Blind, Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1349572 Monotherapy Versus Placebo Over 10 Days in HIV-1 Infected Adults (ING111521).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
- Sponsors ViiV Healthcare
- 29 Jun 2011 Results published in AIDS.
- 19 Feb 2010 Results were presented at the 17th Conference on Retroviruses and Opportunistic Infections (CROI-2010).
- 14 Nov 2009 Results presented at the 12th European AIDS Conference.